Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

BioPharma research is appreciating the trend to cell, gene, and AI therapies – directed toward precision medicine

Contralant, March 20, 2023 The new frontiers of pharmaceutical innovation – according to investors ​ https://www.pharmaceutical-technology.com/sponsored/the-new-frontiers-of-pharmaceutical-innovation-according-to-investors/

Although appreciating the momentum behind pharmaceutical innovation can help entrepreneurs plan for the future, many are still grappling with supply chain and cost pressures in the present. High interest rates mean investors are wary and loans are harder to come by. Firms seeking to raise capital, expand their scope and maintain profitability need to scrutinise their operational efficiency. A renewed focus on supply chain durability can help pharma firms weather present storms and prepare them for changes coming down the line. In addition to providing an end-to-end view of supplier resilience and performance – allowing costs and inefficiencies to be identified and ironed out – modern supply chain monitoring platforms incorporate AI technology, enabling development of increasingly personalised customer engagement strategies. In a world where fine margins are dictating where investors will or will not invest, creating a supply chain that is both efficient and tech-forward today will help rake in funding tomorrow. “Trends such as the focus on cell and gene therapies and the use of AI technology have a knock-on effect for the future of the pharma supply chain, which will need to cater to more individualized therapies,” says Adalheidur Pálmadóttir, VP business development at Controlant. “Changes on the horizon include real-time unit-level tracking, the ability to ramp up and down manufacturing on a massive scale, and the ability to use just-in-time delivery systems across production lines.” Irrespective of size, region or research area, any pharma firm aiming to attract investment must contend with these key trends. “Placing resilient, efficient supply chains at the heart of their operations is imperative,” says Pálmadóttir. “A real-time visibility platform, command centre, and IoT devices are the foundation of digitalised, automated, sustainable supply chains, which is why some of the world’s biggest pharma companies are already working with Controlant.”

Sign in to recut, update, or save this card.